Friday, June 15, 2012

Novartis Presents Data on Gilenya - Analyst Blog by the Intuitive Group

Novartis AG (NVS) recently announced new long-term data from an extended phase III head-to-head TRANSFORMS study, which evaluated its multiple sclerosis (MS) candidate Gilenya (fingolimod). The ...

via Headlines

8233 Old Courthouse Rd Ste 330 Vienna V.A. 22182

Matt Sileno

The Intuitive Group Inc

No comments:

Post a Comment